Prostate cancer: Cardiovascular mortality and androgen deprivation

Nature Reviews Urology

Volumn 6, Issue 5, 2009, Pages 252-253

  Basaria, Shehzad ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; HUMAN; INSULIN RESISTANCE; MEDICAL RESEARCH; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TESTOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; MALE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; NOTE; PROSTATE TUMOR; RISK FACTOR;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 77449120225     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.75     Document Type: Short Survey

References (10)

1. Laaksonen, D. e. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27, 1036-1041 (2004).
2. Malkin, C. J. et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 3313-3318 (2004).
3. Laughlin, G. A., Barrett-Connor, e.&Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68-75 (2008).
4. smith, J. C. et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86, 4261-4267 (2001).
5. Basaria, s., Muller, D. C., Carducci, M. A., egan, J.&Dobs, A. s. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106, 581-588 (2006).
6. Braga-Basaria, M. et al. Metabolic syndrome in men with prostate cancer undergoing longterm androgen-deprivation therapy. J. Clin. Oncol. 24, 3979-3983 (2006).
7. Keating, n. L., O'Malley, A. J.&smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006).
8. D'Amico, A. v. et al. influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25, 2420-2425 (2007).
9. Tsai, H. K., D'Amico, A. v., sadetsky, n., Chen, M. H.&Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516-1524 (2007).
10. efstathiou, J. A. et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 27, 92-99 (2009).